Detection of cognitive changes (mild cognitive impairment and dementia) using DemTect - a validated neurocognitive screening instrument. Mental and Behavioural Disorders
Conditions
Interventions
Since this study is a crossover trial, all participants will receive both IA-DemTect and SA-DemTect and will act as their own controls. Eligible participants will be randomly assigned in a 1:1 allocat
Sponsors
University of Zurich
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: 1. Aged 18 years or older 2. Fluent in German (reading and writing) 3. No documented neuropsychiatric disturbances influencing cognitive ability and ability to follow the study procedures 4. Have a mobile phone 5. Provided informed consent
Exclusion criteria
Exclusion criteria: All individuals not fulfilling the previously mentioned inclusion criteria will be excluded.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Degree to which the SA- and IA-DemTect scores and sub-scores agree with each other (assessed by the intraclass correlation coefficient). SA- and IA-DemTect scores are assessed at baseline and week three. | — |
Secondary
| Measure | Time frame |
|---|---|
| 1. Agreement (assessed by kappa coefficients) of SA- and IA-DemTect in the classification of cognitive impairment (none, mild and significant cognitive impairment). SA- and IA-DemTect scores are assessed at baseline and week three. 2. Agreement of the two SA-DemTect assessments scores with each other (i.e., at-home versus clinical setting), as measured at baseline or week three (depending on the allocation sequence) and week six. 3. Differences in completion times of SA- and IA-DemTect assessments, measured at baseline and week three. 4. Usability of SA-DemTect evaluated at week six using participant questionnaires, and 5. Participant preferences with regards to the SA- and IA-DemTect evaluated at week six using participant questionnaires. | — |
Countries
Switzerland
Contacts
Public ContactTala Ballouz
Outcome results
None listed